Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 2/20 | 0.34 |
| ▸ | KIT | P10721 | 2/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18308371 | 0.92 | MAP2K1 (0.35) | EGFRERBB2GAKACP1RAF1 | |
| SCHEMBL18308508 | 0.82 | KIT (0.38) | EGFRERBB2CSF1RKIT | |
| SCHEMBL18308509 | 0.75 | PLK1 (0.38) | EGFRERBB2RAF1MAP2K1 | |
| SCHEMBL18308389 | 0.73 | MET (0.34) | — | |
| SCHEMBL18308334 | 0.73 | MAPT (0.33) | — | |
| SCHEMBL18308342 | 0.72 | PDE2A (0.36) | PTK2 | |
| SCHEMBL18308505 | 0.71 | MAPT (0.34) | KIT | |
| SCHEMBL18308384 | 0.71 | APLNR (0.35) | — | |
| SCHEMBL18308554 | 0.71 | BRD4 (0.32) | PDE4B | |
| SCHEMBL18308331 | 0.71 | RECQL (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016199943-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-15 | — | — | WO | disclosed |